Leukemia Articles

FDA Approves Arsenic Trioxide for Promyelocytic Leukemia
The FDA has approved arsenic trioxide (Trisenox) in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML-RARA gene expression.
Combination Therapies Poised to Improve CLL Treatment Landscape
Aaron Logan, MD, PhD, discusses the most promising combinations and available treatments for patients with chronic lymphocytic leukemia.
Venetoclax Demonstrates Strong Activity in CLL After BCR Inhibitor
Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).
Plethora of New Drugs in AML Stirs Hope
After several decades without a new therapy, the approval of 4 treatments for acute myeloid leukemia over the span of just 4 months is either a total coincidence or an inevitable occurrence.
A new drug application has been submitted for ivosidenib for patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.
FDA Updates Nilotinib CML Label With Discontinuation Provision
The FDA has updated the label for nilotinib with a provision stipulating that patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase who have received the BCR-ABL tyrosine kinase inhibitor for at least 3 years and have achieved specific predetermined criteria may be eligible to stop treatment.
Venetoclax Combo Reaches High CR Rate in Older AML Patients
Two-thirds of older patients with acute myeloid leukemia achieved complete responses with the combination of venetoclax (Venclexta) and cytarabine.
FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
The FDA has approved bosutinib as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Selinexor Highly Active in Relapsed/Refractory AML
Almost half of patients with relapsed/refractory acute myeloid leukemia achieved complete response with the combination of selinexor (KPT-330) and AraC-containing chemotherapy.
Promising Results in CLL for Frontline Ibrutinib Plus Chemoimmunotherapy
Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.
Publication Bottom Border
Border Publication